Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo to acquire 2% of own shares

This article was originally published in Scrip

Executive Summary

The board of Daiichi Sankyohas approved a new buyback plan under which the firm will acquire up to 15 million of its own outstanding ordinary shares for a maximum of ¥50 billion ($470.0 million) over the July-August period. The total represents around 2% of the company's outstanding shares. Takeda is planning to cancel around 2% of its shares under a similar programme, as part of efforts by major Japanese pharma firms to improve shareholder returns and to guard against any potential hostile takeover bid through the open market.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts